Association of Two Polymorphisms with Breast Cancer Susceptibility in Chinese Han Women

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2018 May 8

PMID 29731666

Citations 13

Authors

Tian Tian

Meng Wang

Yi Zheng

Tielin Yang

Wenge Zhu

Hongtao Li

Shuai Lin

Kang Liu

Peng Xu

Yujiao Deng

Linghui Zhou

Zhijun Dai

Affiliations

Soon will be listed here.

Abstract

Background: Forkhead box P3 () is a key gene in the immune system which also plays a role in tumor development. This study aims to explore the association of two polymorphisms (rs3761548 and rs3761549) with susceptibility to breast cancer (BC).

Method: A case-control study was conducted, involving 560 patients and 583 healthy individuals from the Chinese Han population. The genotypes of polymorphisms were detected using the Sequenom MassARRAY method. The association between polymorphisms and BC risk was evaluated using a χ test with an odds ratio (OR) and 95% confidence intervals (95% CIs) under six genetic models. False-positive report probability was utilized to examine whether the significant findings were noteworthy.

Results: We observed that rs3761548 was associated with a higher BC risk in heterozygous, dominant, overdominant, and allele genetic models (CA vs CC: OR =1.32, =0.031; CA/AA vs CC: OR =1.32, =0.023; CA vs CC/AA: OR =1.29, =0.042; A vs C: OR =1.26, =0.029), whereas no significant association was found between rs3761549 and BC risk. In addition, CA, CA/AA genotype, and A allele of rs3761548 were related to larger tumor size, and the A allele was also correlated with a positive status of Her-2 in BC patients.

Conclusion: Our study suggests that polymorphism rs3761548 is associated with BC susceptibility in the Chinese and may be involved in tumor progression. Future studies are needed to confirm the results in a larger population with more races.

Citing Articles

A systematic review of candidate genes and their relevant pathways for metastasis among adults diagnosed with breast cancer.

Gehling G, Alfaqih M, Pruinelli L, Starkweather A, Dungan J Breast Cancer Res. 2024; 26(1):165.

PMID: 39593069 PMC: 11590482. DOI: 10.1186/s13058-024-01914-6.

Interleukins (Cytokines) as Biomarkers in Colorectal Cancer: Progression, Detection, and Monitoring.

Maryam S, Krukiewicz K, Ul Haq I, Khan A, Yahya G, Cavalu S J Clin Med. 2023; 12(9).

PMID: 37176567 PMC: 10179696. DOI: 10.3390/jcm12093127.

Impact of MIR31HG polymorphisms on risk of breast cancer in Chinese women.

Wei Y, Wang X, Zhang Z, Zhao C, Chang Y, Bian Z Int J Clin Oncol. 2023; 28(5):664-679.

PMID: 36884100 DOI: 10.1007/s10147-023-02323-z.

Polymorphisms Contributed to Breast Cancer Susceptibility in Chinese Han Population.

Wang Y Front Oncol. 2021; 11:657168.

PMID: 34178643 PMC: 8222685. DOI: 10.3389/fonc.2021.657168.

Forkhead box P3 promotes breast cancer cell apoptosis by regulating programmed cell death 4 expression.

Fan D, Zeng C, Wang S, Han J, Zhu L, Zhao H Oncol Lett. 2020; 20(6):292.

PMID: 33101486 PMC: 7576988. DOI: 10.3892/ol.2020.12155.

References

Raskin L, Rennert G, Gruber S . FOXP3 germline polymorphisms are not associated with risk of breast cancer. Cancer Genet Cytogenet. 2009; 190(1):40-2. DOI: 10.1016/j.cancergencyto.2008.12.005. View

Chen L, Yu Q, Liu B, Zhu L . Association of FoxP3 rs3761548 polymorphism with susceptibility to colorectal cancer in the Chinese population. Med Oncol. 2014; 31(12):374. DOI: 10.1007/s12032-014-0374-0. View

Lopes L, Guembarovski R, Guembarovski A, Kishima M, Zago Campos C, Oda J . FOXP3 transcription factor: a candidate marker for susceptibility and prognosis in triple negative breast cancer. Biomed Res Int. 2014; 2014:341654. PMC: 4022106. DOI: 10.1155/2014/341654. View

Katoh M, Igarashi M, Fukuda H, Nakagama H, Katoh M . Cancer genetics and genomics of human FOX family genes. Cancer Lett. 2012; 328(2):198-206. DOI: 10.1016/j.canlet.2012.09.017. View

Tan D, Marchio C, Reis-Filho J . Hereditary breast cancer: from molecular pathology to tailored therapies. J Clin Pathol. 2008; 61(10):1073-82. DOI: 10.1136/jcp.2008.057950. View

Whibley C, Pharoah P, Hollstein M . p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009; 9(2):95-107. DOI: 10.1038/nrc2584. View

Fontenot J, Gavin M, Rudensky A . Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003; 4(4):330-6. DOI: 10.1038/ni904. View

Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin J, Friedman E, Slingerland J . Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. CA Cancer J Clin. 2017; 67(5):378-397. PMC: 5591063. DOI: 10.3322/caac.21405. View

Jiang W, Zheng L, Xu L, Zhang Y, Liu X, Hu L . Association between FOXP3 gene polymorphisms and risk of differentiated thyroid cancer in Chinese Han population. J Clin Lab Anal. 2016; 31(5). PMC: 6817120. DOI: 10.1002/jcla.22104. View

10.

Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N . Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004; 96(6):434-42. PMC: 7713993. DOI: 10.1093/jnci/djh075. View

11.

Bennett C, Christie J, Ramsdell F, Brunkow M, Ferguson P, Whitesell L . The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001; 27(1):20-1. DOI: 10.1038/83713. View

12.

Loktionov A . Common gene polymorphisms, cancer progression and prognosis. Cancer Lett. 2004; 208(1):1-33. DOI: 10.1016/j.canlet.2004.02.009. View

13.

He J, Wang F, Zhu J, Zhang R, Yang T, Zou Y . Association of potentially functional variants in the XPG gene with neuroblastoma risk in a Chinese population. J Cell Mol Med. 2016; 20(8):1481-90. PMC: 4956948. DOI: 10.1111/jcmm.12836. View

14.

Brunkow M, Jeffery E, Hjerrild K, Paeper B, Clark L, Yasayko S . Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet. 2001; 27(1):68-73. DOI: 10.1038/83784. View

15.

Sachidanandam R, Weissman D, Schmidt S, Kakol J, Stein L, Marth G . A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001; 409(6822):928-33. DOI: 10.1038/35057149. View

16.

Triulzi T, Tagliabue E, Balsari A, Casalini P . FOXP3 expression in tumor cells and implications for cancer progression. J Cell Physiol. 2012; 228(1):30-5. DOI: 10.1002/jcp.24125. View

17.

Tan B, Anaka M, Deb S, Freyer C, Ebert L, Chueh A . FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis. Oncotarget. 2014; 5(1):264-76. PMC: 3960207. DOI: 10.18632/oncotarget.1600. View

18.

Jahan P, Ramachander V, Maruthi G, Nalini S, Latha K, Murthy T . Foxp3 promoter polymorphism (rs3761548) in breast cancer progression: a study from India. Tumour Biol. 2013; 35(4):3785-91. DOI: 10.1007/s13277-013-1501-9. View

19.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

20.

He Y, Bo Q, Yong W, Qiu Z, Li Y, Li W . FoxP3 genetic variants and risk of non-small cell lung cancer in the Chinese Han population. Gene. 2013; 531(2):422-5. DOI: 10.1016/j.gene.2013.08.066. View